Partnership Aimed at Enhancing Access to Moderna's mRNA Respiratory Vaccines in Japan

Monday, 8 July 2024, 20:12

The partnership between Moderna and Mitsubishi Tanabe Pharma Corporation aims to boost the availability and promotion of Moderna's mRNA respiratory vaccines in Japan. This collaboration includes a focus on expanding the portfolio to include COVID-19 vaccines, catering to the growing demand for advanced vaccine solutions. By joining forces, both companies strive to address the critical healthcare needs in Japan and contribute to the fight against respiratory illnesses, notably during the ongoing COVID-19 pandemic.

Investing.com — Partnership Aimed at Enhancing Access to Moderna's mRNA Respiratory Vaccines in Japan

Moderna and Mitsubishi Tanabe Pharma Corporation Collaboration

The partnership between Moderna and Mitsubishi Tanabe Pharma Corporation aims to boost the availability and promotion of Moderna's mRNA respiratory vaccines in Japan.

Enhancing Vaccine Portfolio

This collaboration includes a focus on expanding the portfolio to include COVID-19 vaccines, catering to the growing demand for advanced vaccine solutions.

Joint effort to expand mRNA vaccine options in Japan
Emphasis on promoting respiratory vaccine portfolio

Both companies strive to address critical healthcare needs in Japan and contribute to fighting respiratory illnesses, notably during the ongoing COVID-19 pandemic.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Moderna and Mitsubishi Tanabe Pharma Corporation Collaboration

Enhancing Vaccine Portfolio

Related posts